AYALA PHARMACEUTICALS, INC. — Net Income by Fiscal Year
22 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7c92a9d1-8a34-4ecf-ba64-780b9c46d007/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-48.1M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-014822 |
| FY 2022 | $-38.0M | 2022-01-01 – 2022-12-31 | evidence 0001493152-24-014822 |
| FY 2021 | $-17.9M | 2020-11-01 – 2021-10-31 | evidence 0001493152-22-004469 |
| FY 2020 | $-26.5M | 2019-11-01 – 2020-10-31 | evidence 0001493152-21-001656 |
| FY 2019 | $-16.6M | 2018-11-01 – 2019-10-31 | evidence 0001493152-19-019523 |
| FY 2018 | $-66.5M | 2017-11-01 – 2018-10-31 | evidence 0001493152-19-000489 |
| FY 2017 | $-93.4M | 2016-11-01 – 2017-10-31 | evidence 0001493152-19-000489 |
| FY 2016 | $-73.6M | 2015-11-01 – 2016-10-31 | evidence 0001493152-17-000250 |
| FY 2015 | $-47.0M | 2014-11-01 – 2015-10-31 | evidence 0001493152-16-006703 |
| FY 2014 | $-16.5M | 2013-11-01 – 2014-10-31 | evidence 0001493152-15-000050 |
| FY 2013 | $-72.7M | 2002-03-01 – 2014-01-31 | evidence 0001144204-14-016138 |
| FY 2012 | $-58.5M | 2002-03-01 – 2013-04-30 | evidence 0001144204-13-034985 |
| FY 2011 | $-42.5M | 2002-03-01 – 2012-04-30 | evidence 0001144204-12-056844 |
| FY 2010 | $-10.8M | 2009-11-01 – 2010-10-31 | evidence 0001144204-12-004201 |
| FY 2009 | $929.2k | 2008-11-01 – 2009-10-31 | evidence 0001144204-12-004201 |
| FY 2008 | $-5.4M | 2007-11-01 – 2008-10-31 | evidence 0001144204-12-004201 |
| FY 2007 | $-2.5M | 2006-11-01 – 2007-10-31 | evidence 0001144204-12-004201 |
| FY 2006 | $-6.2M | 2005-11-01 – 2006-10-31 | evidence 0001144204-12-004201 |
| FY 2005 | $-1.8M | 2004-11-01 – 2005-10-31 | evidence 0001144204-12-004201 |
| FY 2004 | $-538.1k | 2004-01-01 – 2004-10-31 | evidence 0001144204-12-004201 |
| FY 2003 | $-909.7k | 2003-01-01 – 2003-12-31 | evidence 0001144204-12-004201 |
| FY 2002 | $-166.9k | 2002-03-01 – 2002-12-31 | evidence 0001144204-12-004201 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
AYALA PHARMACEUTICALS, INC. — all facts · Revenue · Operating Income